{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:56:20Z","timestamp":1761872180128,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clml.2022.07.016","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T02:29:55Z","timestamp":1659493795000},"page":"894-902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and Outcomes of Alberta Lymphoma Patients with a History of Immunosuppressive therapy for Autoimmune Conditions"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0051-889X","authenticated-orcid":false,"given":"Kosha","family":"Kantharia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1708","authenticated-orcid":false,"given":"Carolyn","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5650-1216","authenticated-orcid":false,"given":"Patrick","family":"Yau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deonne","family":"Dersch-Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.07.016_bib0001","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/annonc\/mdu365","article-title":"Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study","volume":"25","author":"Fallah","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.07.016_bib0002","doi-asserted-by":"crossref","unstructured":"Ji Y, Lu H. Malignancies in HIV-Infected and AIDS Patients. In: Cai Q, Yuan Z, Lan K, eds. Infectious Agents Associated Cancers: Epidemiology and Molecular Biology. 1018. Advances in Experimental Medicine and Biology. Springer Singapore; 2017:167-179. doi:10.1007\/978-981-10-5765-6_10.","DOI":"10.1007\/978-981-10-5765-6_10"},{"key":"10.1016\/j.clml.2022.07.016_bib0003","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-Transplant Lymphoproliferative Disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2022.07.016_bib0004","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1586\/eci.10.36","article-title":"Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease","volume":"6","author":"Bewtra","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.clml.2022.07.016_bib0005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clml.2022.07.016_bib0006","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy risk and recurrence with psoriasis and its treatments: a concise update","volume":"19","author":"Geller","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clml.2022.07.016_bib0007","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/jgh.12015","article-title":"Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: A review: Lymphoproliferative disorders in inflammatory bowel disease","volume":"28","author":"Subramaniam","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.clml.2022.07.016_bib0008","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/PAS.0000000000001271","article-title":"Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors","volume":"43","author":"Kurita","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2022.07.016_bib0009","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3960\/jslrt.19014","article-title":"Iatrogenic immunodeficiency-associated lymphoproliferative disorders of B-cell type that develop in patients receiving immunosuppressive drugs other than in the post-transplant setting","volume":"59","author":"Momose","year":"2019","journal-title":"J Clin Exp Hematop JCEH"},{"year":"2017","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","key":"10.1016\/j.clml.2022.07.016_bib0010"},{"key":"10.1016\/j.clml.2022.07.016_bib0011","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"10","author":"Hoshida","year":"2022","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clml.2022.07.016_bib0012","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/acr.22306","article-title":"Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients","volume":"66","author":"Kameda","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clml.2022.07.016_bib0013","first-page":"1","article-title":"Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study","volume":"7","author":"Nakano","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.clml.2022.07.016_bib0014","unstructured":"WHOCC - ATC\/DDD Index. Available at: https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed July 27, 2020"},{"key":"10.1016\/j.clml.2022.07.016_bib0015","doi-asserted-by":"crossref","first-page":"AB131","DOI":"10.1016\/j.jaad.2018.05.546","article-title":"Epidemiology of diffuse large B-cell lymphoma in Canada","volume":"79","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2022.07.016_bib0016","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Supplement","key":"10.1016\/j.clml.2022.07.016_bib0017","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1097\/01.tp.0000186382.81130.ba","article-title":"Malignancy after Transplantation","volume":"80","author":"Buell","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2022.07.016_bib0018","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein\u2013Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.07.016_bib0019","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/v14010115","article-title":"New evidence of significant association between ebv presence and lymphoproliferative disorders susceptibility in patients with rheumatoid arthritis: a systematic review with meta-analysis","volume":"14","author":"Banko","year":"2022","journal-title":"Viruses"},{"year":"2021","series-title":"A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication","author":"Carter","key":"10.1016\/j.clml.2022.07.016_bib0020"},{"key":"10.1016\/j.clml.2022.07.016_bib0021","unstructured":"B-Cell Lymphomas NCCN Guidelines [Internet]. b-cell.pdf. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed May 17, 2021"},{"key":"10.1016\/j.clml.2022.07.016_bib0022","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/1756-185X.12823","article-title":"Rheumatoid arthritis: past, present and future approaches to treating the disease","volume":"20","author":"Hyndman","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clml.2022.07.016_bib0023","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clml.2022.07.016_bib0024","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.016_bib0025","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ajh.21753","article-title":"Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis","volume":"85","author":"Adams","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.07.016_bib0026","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3949\/ccjm.85a.17034","article-title":"Hydroxychloroquine: an old drug with new relevance","volume":"85","author":"Shippey","year":"2018","journal-title":"Cleve Clin J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:41Z","timestamp":1761871301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2152265022002361"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and Outcomes of Alberta Lymphoma Patients with a History of Immunosuppressive therapy for Autoimmune Conditions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}